LUMINATE-1: Primary Analysis and Efficacy Outcomes
Transcript
LUMINATE-1 is a Phase III randomised trial evaluating Lumivara versus physician's choice chemotherapy in patients with HER2-low metastatic breast cancer. The primary endpoint analysis demonstrated a statistically significant improvement in progression-free survival, with consistent benefit observed across pre-specified subgroups. We examine the key findings here.